Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05966220
Recruiting Not applicable

Post Market Clinical Follow-up of Hip Surgery Using FH ORTHO Company Medical Devices.

NCT05966220 · tracked via the Priya Life Science France tracker
Sponsor
FH ORTHO
Phase
Not applicable
Started
2024-01-08
Last updated
2026-02-02

Condition(s) studied

Hip Surgery

Investigational drug(s) / intervention(s)

Hip surgery with FH Ortho devices

Hip surgery with FH Ortho devices: This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma. In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons.

Study summary

The objective of this observatory is to generate additional real life clinical data in accordance with local regulation (i.e. Post-Market Clinical Follow-up (PMCF) study, a study carried out following the European Conformity (CE) marking of a device and intended to answer specific questions relating to clinical safety or performance (i.e. residual risks) of a device when used in accordance with its approved labelling).

The difficulty of such an observatory is to be able to collect data on the different versions of the devices, on the different possible combinations of implants of an arthroplasty. The observatory must also be able to cover devices used in surgery to repair osteoarticular trauma.

The observatory will be based on the principle of a "dynamic" cohort during the inclusion period, i.e. with possible inclusions to replace the premature exits.

Technical solutions will be implemented to facilitate data collection from surgeons (electronic Case Report Form (eCRF) and from patients (Electronic Patient Reported Outcome (ePRO) on phone/tablet/computer).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Any patient undergoing or having undergone implantation of medical devices distributed by FH ORTHO Company for hip arthroplasty and traumatology, used in accordance with their approved Instruction For Use, in one of the centers participating in the Observatory. 2. Patient is at least 18 years of age. 3. Patient agreeing to participate after having been informed orally and in writing (with written consent if required locally). 4. In some countries, such as France, the patient will have to be socially insured to be included in the study. Exclusion Criteria: 1. An infection, or latent infection. 2. A mental or neuromuscular disorder that would create an unacceptable risk of prosthetic instability, failure of prosthetic fixation, or post-operative complications (except for the HIP\&GO Double mobility cemented cup and, if applicable, the associated stems and heads when assembled together). 3. Known Insufficient bone quality and/or bone stock. 4. Known allergy to any component of the material listed on the product label. 5. Metabolic diseases that could compromise bone regrowth. 6. Metabolic and/or vascular treatment or disease that may compromise bone healing or consolidation. 7. Drug dependency. 8. Uncooperative patient unable to follow recommendations. 9. Protected adult

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Clinique Pasteur Guilherand-Granges France Recruiting
Centre Hospitalier Du Haut Bugey Oyonnax France Recruiting
Polyclinique Reims-Courlancy Reims France Recruiting
Clinique Mutualiste La Sagesse Rennes France Recruiting
Clinique de l'Atlantique Saint-Herblain France Recruiting

More FH ORTHO trials in France

FH ORTHO Shoulder Observatory Recruiting
Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis Recruiting
Observational Study to Evaluate Safety and Performance of the Total Ankle Prosthesis, EasyMove® Active, not recruiting
FH ORTHO SAS Knee Observatory Starting soon
Study Conducted on Patients Operated With a FHK ASYMETRIQUE to Confirm Security and Performance of the Device Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05966220 on ClinicalTrials.gov ↗ ← All trials in France